TransMedics Group Inc vs Materials Select Sector SPDR Fund — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Materials Select Sector SPDR Fund trades at $51.45. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | XLB | |
|---|---|---|
Market Cap | $3.06B | — |
Sector | Technology | — |
52-Week High | $150.42 | $53.67 |
52-Week Low | $61.99 | $42.23 |
Enterprise Value | $3.46B | — |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
XLB trades at $51.95, down 0.93% on the day, with technical indicators showing a bullish overall signal driven by moving averages. The ETF offers broad exposure to the materials sector, which is benefiting from infrastructure spending and AI-related demand. Recent news highlights the sector's potential for earnings growth and defensive characteristics in the current market environment.
The materials sector appears well-positioned for continued growth with strong Q2 earnings momentum and AI infrastructure tailwinds. However, investors face risks from cyclical sector exposure and potential geopolitical supply chain disruptions. Current technical strength suggests near-term upside potential, though valuation metrics remain unavailable for detailed fundamental assessment.
Trailing returns across standard periods
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →